Literature DB >> 3065216

Monoclonal antibodies that recognize distinct epitopes of the macrophage type three complement receptor differ in their ability to inhibit binding of Leishmania promastigotes harvested at different phases of their growth cycle.

A Cooper1, H Rosen, J M Blackwell.   

Abstract

The macrophage receptor CR3 has been shown by several investigators to be involved in the binding of Leishmania promastigotes to host macrophages. This receptor is known to recognize iC3b and to mediate direct lectin-like attachment of particles such as yeast zymosan. In the present study, two anti-CR3 monoclonal antibodies, M1/70 and 5C6, which ligate different epitopes of murine CR3, have been used in conjunction with sodium salicyl hydroxamate (Saha; inhibits covalent ester linkages of C3 to an activator surface) to block binding of L. donovani and L. major promastigotes harvested at different phases of their growth cycle. M1/70 inhibited all promastigote binding. 5C6 and Saha blocked in parallel only the binding of peanut agglutinin (PNA)-positive late log and early stationary phase parasites. These results suggest that the binding PNA-positive parasites to CR3 is iC3b-mediated, while entry of the more infective PNA-negative late stationary phase promastigotes into host macrophages may involve direct lectin-like binding to CR3.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3065216      PMCID: PMC1385558     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Fusion of host cell secondary lysosomes with the parasitophorous vacuoles of Leishmania mexicana-infected macrophages.

Authors:  J Alexander; K Vickerman
Journal:  J Protozool       Date:  1975-11

2.  Identification of an infective stage of Leishmania promastigotes.

Authors:  D L Sacks; P V Perkins
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

3.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

4.  The covalent-binding reaction of complement component C3.

Authors:  R B Sim; T M Twose; D S Paterson; E Sim
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

5.  Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b.

Authors:  G D Ross; J A Cain; P J Lachmann
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

6.  A study of the differential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages.

Authors:  J Y Channon; M B Roberts; J M Blackwell
Journal:  Immunology       Date:  1984-10       Impact factor: 7.397

7.  Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes.

Authors:  D G Russell; S D Wright
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

8.  An amphipathic sulphated glycoconjugate of Leishmania: characterization with monoclonal antibodies.

Authors:  E Handman; C L Greenblatt; J W Goding
Journal:  EMBO J       Date:  1984-10       Impact factor: 11.598

9.  Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor.

Authors:  D I Beller; T A Springer; R D Schreiber
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

10.  Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan.

Authors:  R A Ezekowitz; R B Sim; M Hill; S Gordon
Journal:  J Exp Med       Date:  1984-01-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival.

Authors:  Norikiyo Ueno; Mary E Wilson
Journal:  Trends Parasitol       Date:  2012-06-21

2.  Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1.

Authors:  P C Taylor; C Q Chu; C Plater-Zyberk; R N Maini
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  Role of beta-D-galactofuranose in Leishmania major macrophage invasion.

Authors:  Erika Suzuki; Ameria K Tanaka; Marcos S Toledo; Helio K Takahashi; Anita H Straus
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Differential expression of B1-containing transcripts in Leishmania-exposed macrophages.

Authors:  Y Ueda; G Chaudhuri
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

5.  Nonopsonic phagocytosis of zymosan and Mycobacterium kansasii by CR3 (CD11b/CD18) involves distinct molecular determinants and is or is not coupled with NADPH oxidase activation.

Authors:  V Le Cabec; C Cols; I Maridonneau-Parini
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

6.  Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.

Authors:  K J Stacey; J M Blackwell
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  Identification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotes.

Authors:  M Kelleher; A Bacic; E Handman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

8.  Comparison of receptors required for entry of Leishmania major amastigotes into macrophages.

Authors:  R A Guy; M Belosevic
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Effector role of blood monocytes in experimental visceral leishmaniasis.

Authors:  J S Cervia; H Rosen; H W Murray
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Interaction with extracellular matrix proteins influences Lsh/Ity/Bcg (candidate Nramp) gene regulation of macrophage priming/activation for tumour necrosis factor-alpha and nitrite release.

Authors:  S Formica; T I Roach; J M Blackwell
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.